Asmaa A. Khalifa, PhD (1), Mai El-Sayed
Ghoneim, MS(2), Bassma Mahmoud Ali, MS(3)
- Department of Pharmacology and therapeutics, Faculty of Pharmacy and
drug manufacturing, Pharos University, Alexandria, Egypt
- Department of Pharmacology and toxicology, faculty of Pharmacy,
University of Sadat City , Menofia, Egypt
- Department of Special Chemistry, Arab Academy for Sciences and
Technology and Maritime Transport, Alexandria, Egypt
Contact details of Corresponding author :
Name: Asmaa Ahmed Khalifa
Email :
asmaa.khalifa@pua.edu.eg
Phone number: +0201274832271
By the end of 2019, some local health authorities reported significant
number of patients with unkown cause pneumonia. However, all patients
have a common factor that they where in a market in Wuhan, China. On
January 2020, the WHO announced that COVID-19 caused by severe acute
respiratory syndrome coronavirus-2 (SARS-COV-2) is a pandemic disease
(Sanders et al., 2020). This virus
belongs to coronaviruses single-stranded RNA family which can infect
both animals and humans. Till now there is no standard treatment ,
however, massive research efforts were made to manage this novel virus.
To present the therapeutic approches that are currntly avilable, the
understanding of the pathophysiology of the virus is a must.